Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare insider sale under a 10b5-1 plan: Dawn C. Maroney, President and officer of Alignment Healthcare (ALHC), reported a planned disposition of 30,000 shares of common stock on 08/13/2025 at a weighted-average price of $14.9036 per share, executed under a Rule 10b5-1 trading plan adopted 11/25/2024. After the sale, Maroney beneficially owns 2,012,899 shares directly. The filing notes the sale prices ranged from $14.64 to $15.13 and that full allocation details by price will be provided on request.
General Atlantic and affiliated entities disclosed a shared beneficial ownership of 43,993,323 shares of Alignment Healthcare Class A common stock, representing 22.2% of the outstanding shares as of June 30, 2025. The percentage is calculated using the company figure of 198,031,417 shares outstanding reported in the company's quarterly report.
The stake is held across multiple reporting persons including General Atlantic, L.P., several GAP Coinvestments vehicles and General Atlantic (ALN HLTH), L.P. The filing states these affiliated entities may be deemed to share voting and dispositive power over the disclosed shares due to their organizational and partner relationships.
Alignment Healthcare insider disclosure shows Hyong (Ken) Kim, the companys Chief Medical Officer, sold 18,600 shares of common stock on 08/11/2025 at a weighted-average price of $14.539 per share under a Rule 10b5-1 trading plan adopted 03/14/2025. The filing reports Mr. Kim continues to directly beneficially own 490,767 shares after the transaction.
The Form 4 was signed by an attorney-in-fact on 08/13/2025 and notes the executed sale prices ranged from $14.42 to $14.61; the reporting person offers to provide detailed per-price sale counts on request.
Alignment Healthcare, Inc. (ALHC) disclosed a proposed sale of 18,600 common shares under Rule 144, with an aggregate market value of $272,304.00. The shares were originally acquired 03/26/2021 as pre-IPO issuances exchanged for partnership units. The filing names Morgan Stanley Smith Barney LLC as the broker and lists an approximate sale date of 08/13/2025. The notice also records a related 10b5-1 sale executed on 08/11/2025 generating $270,425.40 in gross proceeds. The filer affirms they are not aware of undisclosed material adverse information about the issuer.
Alignment Healthcare insider sale by CEO John E. Kao. The Form 4 discloses that Mr. Kao, who is both a director and the Chief Executive Officer, sold 180,000 shares of Alignment Healthcare common stock on 08/11/2025 pursuant to a Rule 10b5-1 plan adopted on 03/12/2025. The filing reports a weighted-average sale price of $14.5991 with prices in the range $14.42 to $14.80. Following the reported transactions, the filing shows 1,373,100 shares beneficially owned indirectly through the JEK Trust. The form also includes an entry listing 4,888,586 shares marked as disposed with no transaction date shown.
Alignment Healthcare (ALHC) Form 144 summary: The filing notifies a proposed sale of 18,600 shares of common stock on NASDAQ through Morgan Stanley Smith Barney LLC with an aggregate market value of $269,886. The filing reports 198,031,417 shares outstanding. The shares were acquired on 03/26/2021 as pre-IPO shares issued in exchange for partnership units. The filing lists an approximate date of sale of 08/11/2025 and states there were no securities sold in the past three months. By signing the notice the seller represents they do not know of any undisclosed material adverse information about the issuer.
FMR LLC (parent of Fidelity Investments) and its chair Abigail P. Johnson filed Amendment No. 4 to Schedule 13G reporting a passive stake in Alignment Healthcare (ALHC).
- Shares owned: 11,279,800.70 common shares.
- Percent of class: 5.7 % as of the event date 30 Jun 2025.
- Voting power: FMR holds sole voting power over 11,277,456.23 shares; Johnson reports no direct voting power.
- Dispositive power: FMR and Johnson each have sole dispositive power over the full 11.28 m shares; no shared powers are disclosed.
The filing is made under Rule 13d-1(b)/(c), confirming the stake is held in the ordinary course of business with no intent to influence control. The signature is dated 5 Aug 2025 and executed by Richard Bourgelas under existing power of attorney.
Crossing the 5 % threshold positions Fidelity as a significant institutional shareholder, potentially broadening ALHC’s investor base and adding passive support to the stock’s float; however, the filing provides no insight into future trading intentions.
Form 4 filing for Alignment Healthcare (ALHC) shows Director Joseph S. Konowiecki sold 25,000 common shares on 31 Jul 2025 at $16.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted 5 Mar 2025. Gross proceeds equal roughly $400k.
Following the sale, Konowiecki’s direct ownership stands at 1,152,049 shares. No derivative securities were reported. The transaction does not alter board status and no other insider activity is disclosed in this filing.
Alignment Healthcare, Inc. (ALHC) — Form 144 filing
An insider intends to sell up to 25,000 common shares (≈0.013% of the 198,031,417 shares outstanding) through broker Justin Tabit on or about 31 Jul 2025. The shares, valued at an estimated $398,750, were originally received on 6 Oct 2014 as equity awards from Joseph Konowiecki. No related sales have been made in the past three months. The filer confirms possession of no undisclosed material adverse information and notes potential reliance on a Rule 10b5-1 trading plan.